BIOCIUS Life Sciences and BlueSky Biotech Extend Partnership, Provide Validated Enzymes Fully‐Validated SIRT1 Enhances Drug Discovery Investigation
Worcester, MA, June 18, 2010 --(PR.com)-- BIOCIUS Life Sciences Inc., developers of the RapidFire® highthroughputmass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry’s only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully validated in a label‐free functional assay. This collaboration builds on an existing partnership and will significantly improve drug discovery efficiency of the SIRT class of epigenetic modulating enzymes, which are being heavily investigated as promising therapeutics for several indications.
The collaboration intends to launch a selectivity panel of sirtuins and histone deacetylases (HDACs). The activity of the first release, SIRT1, has been linked to the regulation of multiple cellular processesincluding insulin signaling, apoptosis, and cancer, making SIR 1 an important therapeutic target for avariety of conditions. The two companies plan to release additional validated enzymes over the course of the coming months.
“Our latest endeavor with BIOCIUS provides researchers with a pre‐validated assay solution that saves time and money, and further demonstrates the synergy of our high quality proteins combined with BIOCIUS’s value‐added screening solutions,” said Paul Wengender, CEO, Blue Sky Biotech, Inc. According to William LaMarr, Vice President of Research and Contract Services at BIOCIUS, “validation using a label‐free, functional assay is especially important for sirtuins given the controversy surrounding fluorescent based assays recently seen in the scientific literature.”
About BIOCIUS Life Sciences, Inc.
Named from the Greek word “BIO” (life) and the Latin word “OCIUS” (faster), BIOCIUS Life Sciences, provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS’s products and contract research services enable our partners to exceed their business goals.
About BlueSky Biotech
Blue Sky Biotech, Inc. is an integrated provider of custom biologicals for biomedical research and drug discovery and is organized into two divisions: BioServices and BioProducts. The BioServices division offers a wide range of custom services spanning Molecular Biology, Eukaryotic and Prokaryotic Protein Expression, Protein Purification, and Assay Development. This suite of pre-clinical services provides our clients with a convenient source of high quality custom research tools. Blue Sky also invests heavily in technology development to improve or enhance its production capabilities, including a proprietary process technology (IKM®) that significantly reduces cycle times and enhances reproducibility of protein production using baculovirus-mediated insect cell expression. The BioProducts division offers high quality biologicals and membrane protein solutions (TDA™ and SmartscreenTM Kits) designed to facilitate drug discovery. The company is a privately held corporation with over 40 staff members. It is located in Worcester, MA. For more information, please visit www.blueskybiotech.com.
###
The collaboration intends to launch a selectivity panel of sirtuins and histone deacetylases (HDACs). The activity of the first release, SIRT1, has been linked to the regulation of multiple cellular processesincluding insulin signaling, apoptosis, and cancer, making SIR 1 an important therapeutic target for avariety of conditions. The two companies plan to release additional validated enzymes over the course of the coming months.
“Our latest endeavor with BIOCIUS provides researchers with a pre‐validated assay solution that saves time and money, and further demonstrates the synergy of our high quality proteins combined with BIOCIUS’s value‐added screening solutions,” said Paul Wengender, CEO, Blue Sky Biotech, Inc. According to William LaMarr, Vice President of Research and Contract Services at BIOCIUS, “validation using a label‐free, functional assay is especially important for sirtuins given the controversy surrounding fluorescent based assays recently seen in the scientific literature.”
About BIOCIUS Life Sciences, Inc.
Named from the Greek word “BIO” (life) and the Latin word “OCIUS” (faster), BIOCIUS Life Sciences, provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS’s products and contract research services enable our partners to exceed their business goals.
About BlueSky Biotech
Blue Sky Biotech, Inc. is an integrated provider of custom biologicals for biomedical research and drug discovery and is organized into two divisions: BioServices and BioProducts. The BioServices division offers a wide range of custom services spanning Molecular Biology, Eukaryotic and Prokaryotic Protein Expression, Protein Purification, and Assay Development. This suite of pre-clinical services provides our clients with a convenient source of high quality custom research tools. Blue Sky also invests heavily in technology development to improve or enhance its production capabilities, including a proprietary process technology (IKM®) that significantly reduces cycle times and enhances reproducibility of protein production using baculovirus-mediated insect cell expression. The BioProducts division offers high quality biologicals and membrane protein solutions (TDA™ and SmartscreenTM Kits) designed to facilitate drug discovery. The company is a privately held corporation with over 40 staff members. It is located in Worcester, MA. For more information, please visit www.blueskybiotech.com.
###
Contact
Blue Sky Biotech
Brian Cain
800-383-7795
www.blueskybiotech.com
Brian Cain
800-383-7795
www.blueskybiotech.com
Contact
Categories